$5.06 Billion is the total value of Rock Springs Capital Management LP's 156 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IDXX | IDEXX LABS INC | $113,679,000 | +29.1% | 180,000 | 0.0% | 2.25% | +17.0% | |
| ISRG | INTUITIVE SURGICAL INC | $110,357,000 | +24.5% | 120,000 | 0.0% | 2.18% | +12.7% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $98,780,000 | +0.1% | 1,015,000 | 0.0% | 1.95% | -9.3% | |
| HCA | HCA HEALTHCARE INC | $93,033,000 | +9.8% | 450,000 | 0.0% | 1.84% | -0.5% | |
| FRPT | FRESHPET INC | $82,539,000 | +2.6% | 506,500 | 0.0% | 1.63% | -7.1% | |
| EXAS | EXACT SCIENCES CORP | $70,857,000 | -5.7% | 570,000 | 0.0% | 1.40% | -14.6% | |
| BGNE | BEIGENE LTDsponsored adr | $68,638,000 | -1.4% | 200,000 | 0.0% | 1.36% | -10.7% | |
| PCRX | PACIRA BIOSCIENCES INC | $62,197,000 | -13.4% | 1,025,000 | 0.0% | 1.23% | -21.6% | |
| EW | EDWARDS LIFESCIENCES CORP | $60,278,000 | +23.8% | 582,000 | 0.0% | 1.19% | +12.1% | |
| HZNP | HORIZON THERAPEUTICS PUB L | $58,525,000 | +1.7% | 625,000 | 0.0% | 1.16% | -7.8% | |
| TFX | TELEFLEX INCORPORATED | $52,233,000 | -3.3% | 130,000 | 0.0% | 1.03% | -12.4% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $50,856,000 | +20.1% | 300,000 | 0.0% | 1.00% | +8.8% | |
| ACHC | ACADIA HEALTHCARE COMPANY IN | $43,925,000 | +9.8% | 700,000 | 0.0% | 0.87% | -0.6% | |
| HCAT | HEALTH CATALYST INC | $43,575,000 | +18.7% | 785,000 | 0.0% | 0.86% | +7.5% | |
| SWAV | SHOCKWAVE MED INC | $41,741,000 | +45.7% | 220,000 | 0.0% | 0.82% | +32.0% | |
| PEN | PENUMBRA INC | $40,424,000 | +1.3% | 147,500 | 0.0% | 0.80% | -8.3% | |
| SGEN | SEAGEN INC | $39,470,000 | +13.7% | 250,000 | 0.0% | 0.78% | +3.0% | |
| BIIB | BIOGEN INC | $39,302,000 | +23.8% | 113,500 | 0.0% | 0.78% | +12.1% | |
| EHC | ENCOMPASS HEALTH CORP | $39,015,000 | -4.7% | 500,000 | 0.0% | 0.77% | -13.7% | |
| NVCR | NOVOCURE LTD | $38,819,000 | +67.8% | 175,000 | 0.0% | 0.77% | +51.9% | |
| BSX | BOSTON SCIENTIFIC CORP | $34,208,000 | +10.6% | 800,000 | 0.0% | 0.68% | +0.1% | |
| PPD | PPD INC | $31,111,000 | +21.8% | 675,000 | 0.0% | 0.62% | +10.4% | |
| ASND | ASCENDIS PHARMA A/Ssponsored adr | $30,717,000 | +2.1% | 233,500 | 0.0% | 0.61% | -7.6% | |
| CGEM | CULLINAN ONCOLOGY INC | $27,705,000 | -38.2% | 1,075,912 | 0.0% | 0.55% | -44.0% | |
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $26,559,000 | +1.5% | 650,000 | 0.0% | 0.52% | -8.1% | |
| LUNG | PULMONX CORP | $26,141,000 | -3.5% | 592,500 | 0.0% | 0.52% | -12.5% | |
| ALLK | ALLAKOS INC | $26,098,000 | -25.6% | 305,706 | 0.0% | 0.52% | -32.6% | |
| SRPT | SAREPTA THERAPEUTICS INC | $25,557,000 | +4.3% | 328,750 | 0.0% | 0.50% | -5.6% | |
| GH | GUARDANT HEALTH INC | $24,838,000 | -18.6% | 200,000 | 0.0% | 0.49% | -26.3% | |
| OSH | OAK STR HEALTH INC | $21,964,000 | +7.9% | 375,000 | 0.0% | 0.43% | -2.3% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $21,749,000 | -0.3% | 920,000 | 0.0% | 0.43% | -9.7% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $21,152,000 | +10.5% | 253,500 | 0.0% | 0.42% | 0.0% | |
| CYTOKINETICS INCnote 4.000%11/1 | $16,570,000 | -13.2% | 8,000,000 | 0.0% | 0.33% | -21.6% | ||
| APLT | APPLIED THERAPEUTICS INC | $14,581,000 | +10.8% | 701,680 | 0.0% | 0.29% | +0.3% | |
| EPIX | ESSA PHARMA INC | $14,372,000 | -1.6% | 503,035 | 0.0% | 0.28% | -11.0% | |
| ANAB | ANAPTYSBIO INC | $13,879,000 | +20.3% | 535,232 | 0.0% | 0.27% | +8.7% | |
| SPRO | SPERO THERAPEUTICS INC | $13,484,000 | -5.2% | 965,928 | 0.0% | 0.27% | -14.2% | |
| LEGN | LEGEND BIOTECH CORPsponsored ads | $12,833,000 | +41.5% | 312,618 | 0.0% | 0.25% | +28.3% | |
| GOSSAMER BIO INCnote 5.000% 6/0 | $12,585,000 | -10.0% | 15,573,000 | 0.0% | 0.25% | -18.4% | ||
| GLPG | GALAPAGOS NVspon adr | $11,367,000 | -10.6% | 165,000 | 0.0% | 0.22% | -19.1% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $10,978,000 | -12.1% | 1,577,296 | 0.0% | 0.22% | -20.5% | |
| XENE | XENON PHARMACEUTICALS INC | $10,660,000 | +4.0% | 572,500 | 0.0% | 0.21% | -5.8% | |
| WST | WEST PHARMACEUTICAL SVSC INC | $10,234,000 | +27.4% | 28,500 | 0.0% | 0.20% | +15.4% | |
| OHPAU | ORION ACQUISITION CORPunit 02/19/2026 | $9,920,000 | -0.8% | 1,000,000 | 0.0% | 0.20% | -10.1% | |
| FOLD | AMICUS THERAPEUTICS INC | $9,761,000 | -2.4% | 1,012,506 | 0.0% | 0.19% | -11.5% | |
| FGEN | FIBROGEN INC | $8,327,000 | -23.3% | 312,687 | 0.0% | 0.16% | -30.4% | |
| FUSN | FUSION PHARMACEUTICALS INC | $7,662,000 | -24.6% | 948,327 | 0.0% | 0.15% | -32.0% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $6,582,000 | -19.8% | 1,545,000 | 0.0% | 0.13% | -27.4% | |
| FATE | FATE THERAPEUTICS INC | $6,075,000 | +5.2% | 70,000 | 0.0% | 0.12% | -4.8% | |
| GRTX | GALERA THERAPEUTICS INC | $5,586,000 | +11.5% | 568,252 | 0.0% | 0.11% | +0.9% | |
| BLSA | BCLS ACQUISITION CORP | $3,254,000 | -0.4% | 309,000 | 0.0% | 0.06% | -9.9% | |
| PSTX | POSEIDA THERAPEUTICS INC | $2,903,000 | +4.9% | 289,754 | 0.0% | 0.06% | -5.0% | |
| RETROPHIN INCnote 2.500% 9/1 | $2,765,000 | -17.7% | 3,250,000 | 0.0% | 0.06% | -24.7% | ||
| EUCRU | EUCRATES BIOMEDICAL ACQU CORunit 10/23/2027 | $2,101,000 | +1.8% | 206,000 | 0.0% | 0.04% | -6.7% | |
| TMPMU | TURMERIC ACQUISITION CORPunit 10/08/2025 | $2,072,000 | +0.6% | 206,000 | 0.0% | 0.04% | -8.9% | |
| FSII | FS DEVELOPMENT CORP II | $2,089,000 | +0.2% | 209,332 | 0.0% | 0.04% | -8.9% | |
| JYAC | JIYA ACQUISITION CORP | $2,050,000 | +1.0% | 206,200 | 0.0% | 0.04% | -6.8% | |
| PHICU | POPULATION HEALTH INVS CO INunit 99/99/9999 | $2,041,000 | +1.0% | 201,044 | 0.0% | 0.04% | -9.1% | |
| HLXA | HELIX ACQUISITION CORP | $1,599,000 | +1.5% | 154,500 | 0.0% | 0.03% | -5.9% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $1,393,000 | -0.6% | 1,500,000 | 0.0% | 0.03% | -9.7% | ||
| THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $1,429,000 | -6.4% | 1,500,000 | 0.0% | 0.03% | -15.2% | ||
| NEUROCRINE BIOSCIENCES INCnote 2.250% 5/1 | $1,347,000 | -0.5% | 1,000,000 | 0.0% | 0.03% | -10.0% | ||
| PACIRA BIOSCIENCES INCnote 2.375% 4/0 | $1,094,000 | -9.7% | 1,000,000 | 0.0% | 0.02% | -15.4% | ||
| NEVRO CORPnote 2.750% 4/0 | $866,000 | +12.3% | 500,000 | 0.0% | 0.02% | 0.0% | ||
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $348,000 | -2.8% | 134,028 | 0.0% | 0.01% | -12.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.